You are here
Cosentyx May Benefit Patients With Psoriatic Arthritis
About half of the psoriatic arthritis patients who received subcutaneous infusions of 150 mg or 300 mg of secukinumab (Cosentyx, Novartis) achieved a 20% response to treatment, according to a study published recently in The Lancet.
Helio reported that researchers conducted a phase III, double-blind, placebo-controlled study of 397 patients with psoriatic arthritis at 76 centers in Asia, Australia, Canada, Europe, and the U.S. between April and November 2013. Patients were randomized 1:1:1:1 to treatment with 300-mg subcutaneous secukinumab, 150-mg secukinumab, 75-mg secukinumab, or placebo once a week for the first four weeks and every four weeks thereafter. Patients were included if they had psoriasis in at least 3% of their body area and dactylitis or enthesitis at baseline; 185 received concomitant methotrexate.
At week 24, an American College of Rheumatology (ACR) response rate of 20% (ACR20) was achieved by 54% of patients who received 300-mg secukinumab, 51% of patients who received 150-mg secukinumab, and 29% of patients who received 75-mg secukinumab compared with 15% of patients who received placebo. An improvement in the Psoriasis Area and Severity Index (PASI) score of 75% (PASI 75) and 90% (PASI 90) was seen in significantly more patients who received 300-mg or 150-mg secukinumab compared with 75-mg secukinumab or placebo.
An ACR70 response was observed in 20% of patients who received 300-mg secukinumab, 21% of patients who received 150-mg secukinumab, and 6% of patients who received 75-mg secukinumab compared with 1% of patients who received placebo.
At week 52, 335 of 397 patients remained in the study. Improvements exhibited at week 24 were maintained at week 52 in patients who received 300-mg or 150-mg secukinumab.
No patient deaths were reported during the study and there were no reports of suicide attempts or suicidal ideation. Adverse events occurred with similar incidence across all groups, including placebo, with the exception of a slightly higher rate of serious adverse events in the 300-mg and 75-mg secukinumab groups. The most common adverse event was infection, followed by upper respiratory tract infection and nasopharyngitis.
Sources: Healio; September 21, 2015; The Lancet; September, 2015.